In English | En español
Questions About Cancer? 1-800-4-CANCER

Clinical Trials Search Results

View Content for:
Display:
  •          
Help with display options.
Results 1-25 of 28 for your search:
Drug:  cabozantinib-s-malate
Find trials that include:  Any drugs shown
Trial Status:  Active
Start Over
        Show
1.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: XL184-306, NCT01522443
2.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: XL184-307, 2012-001834-33, NCT01605227
3.

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: UMCC 2011.069, HUM00052320, NCT01428219
4.

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 11-208, NCT01441947
5.

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 11-274, NCT01466036
6.

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 12-091, NCT01588821
7.

Phase: Phase II
Type: Biomarker/Laboratory analysis, Diagnostic, Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: 12-1031, NCI-2012-00677, NCT01599793
8.

Phase: Phase II
Type: Treatment
Status: Approved-not yet active
Age: Not specified
Sponsor: Other
Protocol IDs: 2012-0252, NCT01630590
9.

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 12-097, NCT01639508
10.

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: 120205, 12-C-0205, NCT01688999
11.

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-01938, E1512, U10CA021115, NCT01708954
12.

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-02058, GOG-0186K, U10CA027469, NCT01716715
13.

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 12-431, NCT01738438
14.

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: 130044, 13-C-0044, NCT01755195
15.

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2013-00554, OSU 12154, N01CM00070, NCT01811212
16.

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: PHL-086 / NCI 9322, NCT01815151
17.

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: XL184-IST20, NCT01834651
18.

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2013-00821, A091201, U10CA031946, NCT01835145
19.

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2013-00820, A031203, U10CA031946, NCT01835158
20.

Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 20 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: XL184-014, NCT01553656
21.

Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 11-441, NCT01574937
22.

Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 12-005, NCT01582295
23.

Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: UMCC 2011.105, HUM 62927, NCT01663272
24.

Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: 120204, 12-C-0204, NCT01683994
25.

Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 2 to 18
Sponsor: NCI
Protocol IDs: NCI-2012-01890, ADVL1211, CDR0000741914, U01CA097452, NCT01709435
1   
New Search